HealthQuad is an early-growth healthcare venture firm that backs Indian healthtech startups, and it has now pulled in ₹550 Cr in first-close commitments for HealthQuad Fund III against a target corpus of ₹1,700 Cr. Indian healthtech keeps producing strong products, but specialist capital is still scarce when companies hit the messy middle of regulation, clinical validation, and enterprise sales. Founded in 2016, and now fully controlled by Quadria Group through Amit Varma, Abrar Mir, and Sunil Thakur, the platform wants this fund to support 13-15 startups across AI-driven healthcare, digital therapeutics, ambulatory care, enterprise SaaS, and point-of-care devices.
And this isn’t just a paper launch.
The firm has already made its first Fund III investment — an undisclosed amount into AI-driven patient monitoring startup LifeSigns — while keeping most of the vehicle focused on India and reserving some room for Southeast Asia.
What is HealthQuad Fund III and how does it work?
HealthQuad Fund III is basically a concentrated specialist fund for healthcare founders who need more than a cheque. HealthQuad’s pitch has always been that it brings clinical insight and operating experience. It also offers healthcare networks, policy access, and strategic guidance on top of capital. That makes sense in healthcare, where a flashy demo usually isn’t enough and founders have to survive long buying cycles, hospital procurement, compliance work, and real-world outcome pressure.
The fund is set up to back 13-15 companies, not dozens. That tells you a lot. HealthQuad is choosing depth over spray-and-pray. HealthQuad targets rapidly evolving healthcare categories, including AI-led care delivery, digital therapeutics, ambulatory models, enterprise software for providers, and point-of-care hardware. Most of that capital will go into India, with optional exposure to Southeast Asia where Quadria already has relationships.
The first deal gives a clear read on the thesis. LifeSigns builds remote patient monitoring technology around wearable biosensors and cloud software. Its system uses chest-worn wireless sensors to capture data such as ECG, respiration, skin temperature, motion, and in some versions SpO2. It then streams that information in near real time to a cloud dashboard so clinicians can monitor patients across wards, step-down settings, and hospital-at-home pathways without relying only on fixed bedside machines.
That’s a smart signal. HealthQuad isn’t chasing vague “AI for healthcare” slides. It’s leaning toward products that fit into actual care delivery and can show workflow value fast — fewer blind spots, quicker intervention, and better staff efficiency. In plain English: software is nice, but it has to survive contact with hospitals.
Who runs HealthQuad and what is its track record?
How HealthQuad started
Quadria launched HealthQuad in 2016 as its dedicated early-growth healthcare investing arm, partnered with KIOS for several years, and took full control ahead of Fund III, which HealthQuad Advisors now manages under Amit Varma, Abrar Mir, and Sunil Thakur.
That ownership reset matters more than it sounds.
For a specialist fund, governance clarity is a big deal. Founders want clarity on who makes investment decisions, controls reserves, and provides strategic support after signing a term sheet.
Why the founders fit this market
Amit Varma brings the operator lens. He’s a doctor by training — a critical care physician — and has 33 years of experience across investing, strategy, and operations in the US and Asia. A Business Standard profile adds that he spent a decade in the US before returning to India and worked with Dr. Devi Shetty’s teams managing intensive care operations at Manipal Hospitals and Narayana Hrudayalaya.
Abrar Mir is the finance-heavy counterweight. He has more than 20 years of experience in private equity, investment banking, and healthcare. He previously led global healthcare investment banking at Religare Capital Markets after a stint at Bank of America Merrill Lynch and he also holds an M.Phil in International Law from Cambridge.
Sunil Thakur rounds out the trio with transaction and policy experience. He has 24 years in investing and M&A, with earlier roles at Religare Capital Markets and PNB Gilts. He has led multi-billion-dollar transactions while also engaging with healthcare policy bodies.
That mix is pretty credible for this category. Healthcare founders usually need help across three fronts at once — clinical adoption, capital planning, and institutions — and this team has touched all 3.
What the firm has already built
HealthQuad’s earlier two funds backed 18 startups, including GoApptiv, Qure.ai, Redcliffe Labs, Cureskin, Strand Life Sciences, Medikabazaar, THB, Wysa, and Ekincare. Fund II reached a final close of $162 Mn and had targeted 10-15 early-stage companies across high-growth healthcare segments in India.
The split with KIOS also created a new neighbour. In 2025, the operational leadership that separated from HealthQuad launched HealthKios, with a maiden fund targeting $300 Mn and another $100 Mn available through a greenshoe option. So yes, specialist healthcare capital in India is still a small club — but it’s no longer a one-player niche.
Fundraising details and how HealthQuad is positioned
Fund III launched in July 2025 with a $200 Mn target and a $100 Mn greenshoe option. The current first close brings in ₹550 Cr, or about $58.2 Mn, from a mix of new institutional LPs, family offices, and returning backers. That gives HealthQuad enough room to start deploying seriously, and the first disclosed cheque has already gone to LifeSigns.
Competition comes from two directions. One is other specialist healthcare pools such as HealthKios. The other is older, less structured capital — hospital promoters, family offices, and generalist VC firms that will still do healthtech deals but don’t live and breathe the sector. HealthQuad’s edge is that it stays narrowly healthcare-focused and plugs founders into Quadria’s broader Asia healthcare network instead of acting like a generic seed fund with a medtech slide in the deck.
Why HealthQuad Fund III matters for founders now
A first close changes the conversation. Once capital is actually in, founders stop hearing “we’re raising a fund” and start hearing “let’s talk about diligence, ownership, and timelines.” That’s useful in a market where healthtech companies can’t afford fundraising drift for 9 months while they wait for a specialist investor to finish its own LP process.
It also says something about investor appetite after a rough stretch for digital health. HealthQuad is still betting that there’s room to build large companies in care delivery software, diagnostics, monitoring, and provider infrastructure. But the fund’s narrow portfolio size suggests it wants businesses with sharper execution and clearer economics than the 2020-2022 boom rewarded. Frankly, that’s healthy.
Quadria now fully controls the vehicle, so Fund III looks cleaner than the brand’s transition year did. Founders know which team is underwriting them, which boardroom they’ll be dealing with, and which regional relationships they can tap as they scale. In venture, that kind of clarity is underrated.
Why are investors backing Indian healthtech now?
The timing looks contradictory at first. In Q1 2026, 25 Indian healthtech startups raised $181 Mn, down 40% from $301 Mn in the year-ago quarter. So capital has clearly become more selective.
But the demand story hasn’t gone away. India’s health-tech sector could reach about ₹4,43,500 crore (roughly $50 billion) by 2033, while the broader digital health market may grow from $8.79 billion in 2024 to $47.8 billion by 2033, and the medical devices market could touch $50 billion by 2030–31.
What’s changed is the bar. Investors now want healthcare businesses that can prove adoption inside hospitals, diagnostics chains, insurers, or home-care workflows — not just app installs. AI and automation are helping. Policy support is improving. Care is spreading beyond top-tier urban hospitals. But none of that removes the need for disciplined execution.
What to watch after HealthQuad Fund III's first close
The next thing to watch is pace. If HealthQuad moves quickly from LifeSigns into a few more deals, founders and LPs will read that as confidence. If deployment drags, people will wonder whether the firm is being careful or whether the best companies are already too expensive, too late-stage, or too hard to underwrite.
HealthQuad Fund III isn’t trying to be a broad tech fund with a healthcare filter slapped on top. It’s a sector bet, run by people who’ve spent years inside healthcare finance and operations, at a time when the category is still underfunded relative to its ambition.
Read how Fashion Entrepreneur Fund opened registrations for Pitch To Get Rich Season 2 with a ₹100 crore investment pool, aiming to fund and mentor the next generation of fashion, D2C, and lifestyle startups in India.
FAQ
- What is the latest funding update on HealthQuad Fund III? HealthQuad has announced a first close of ₹550 Cr for HealthQuad Fund III against a target corpus of ₹1,700 Cr. The commitments came from new institutional LPs, family offices, and existing backers, and the fund has already made its first disclosed investment in LifeSigns.
- How does HealthQuad Fund III work for healthtech startups? It works like a specialist early-growth healthcare fund rather than a broad software vehicle. HealthQuad looks for companies in areas such as AI-driven healthcare, digital therapeutics, ambulatory care, enterprise SaaS, and point-of-care devices. It then supports them with sector expertise, clinical context, and access to healthcare networks beyond just capital.
- Who founded HealthQuad and why are they credible healthcare investors? HealthQuad was established in 2016 under Quadria, and Fund III is now controlled by Amit Varma, Abrar Mir, and Sunil Thakur. Varma brings clinical and hospital operating experience, Mir comes from healthcare investment banking and private equity, and Thakur adds deep M&A and policy exposure — which is a strong mix for backing regulated healthcare companies.
- Is HealthQuad focused only on India healthtech? Mostly, yes. Fund III is predominantly allocated to India, though it keeps a discretionary share for Southeast Asia, which fits Quadria’s wider regional footprint in healthcare investing.
